Pierre-François Dequin, Ferhat Meziani, Jean-Pierre Quenot, Toufik Kamel, Jean-Damien Ricard, Julio Badie, Jean Reignier, Nicholas Heming, Gaëtan Plantefève, Bertrand Souweine, Guillaume Voiriot, Gwenhaël Colin, Jean-Pierre Frat, Jean-Paul Mira, Nicolas Barbarot, Bruno François, Guillaume Louis, Sébastien Gibot, Christophe Guitton, Christophe Giacardi, Sami Hraiech, Sylvie Vimeux, Erwan L'Her, Henri Faure, Jean-Etienne Herbrecht, Camille Bouisse, Aurélie Joret, Nicolas Terzi, Arnaud Gacouin, Charlotte Quentin, Mercé Jourdain, Marie Leclerc, Carine Coffre, Hélène Bourgoin, Céline Lengellé, Caroline Caille-Fénérol, Bruno Giraudeau, Amélie Le Gouge
BACKGROUND: Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. METHODS: In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 8 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo...
March 21, 2023: New England Journal of Medicine